23andMe acquired by biotech giant Regeneron after bankruptcy filing

LOS ANGELES – Biotechnology company Regeneron Pharmaceuticals is acquiring genetic testing company 23andMe for $256 million, two months after 23andMe sought Chapter 11 bankruptcy protection amid financial struggles. The deal…